Privia Health reports strong second quarter results, raising guidance across multiple financial metrics compared to previous year.
Quiver AI Summary
Privia Health Group, Inc. reported strong financial results for the second quarter ending June 30, 2025, with total revenue of $521.2 million, a 23.4% increase from the previous year. Key metrics included practice collections rising by 18.5% to $862.9 million and implemented providers increasing by 13.8% to 5,125. Although operating income decreased by 34.6% to $3.3 million, non-GAAP adjusted net income surged by over 30% to $30.6 million. The company has raised its fiscal year 2025 guidance for several financial metrics, including practice collections and adjusted EBITDA, driven by robust growth and operational performance. With $390.1 million in cash and no debt, Privia Health is well-positioned for future expansion and continued success in the healthcare sector.
Potential Positives
- Strong revenue growth of 23.4% year-over-year, reaching $521.2 million for the second quarter of 2025.
- Practice Collections increased by 18.5% year-over-year, totaling $862.9 million, indicating robust performance in client engagements.
- Significant rise in Adjusted EBITDA by 31.6% year-over-year, reaching $29.0 million, showcasing improved operational efficiency.
- Raised full-year guidance for multiple key financial metrics, including Practice Collections and Adjusted EBITDA, indicating management's confidence in continued growth.
Potential Negatives
- Operating income decreased by 34.6% compared to the same period last year, indicating potential challenges in cost management or operational efficiency.
- Net income declined by 22.5% compared to the previous year, raising concerns about the company's profitability trajectory.
- Despite revenue growth, the substantial increase in stock-based compensation expenses may raise questions about overall financial health and resource allocation.
FAQ
What were Privia Health's revenue figures for Q2 2025?
Privia Health reported total revenue of $521.2 million for Q2 2025, a 23.4% increase compared to Q2 2024.
How did Practice Collections perform in Q2 2025?
Practice Collections reached $862.9 million, showing an 18.5% growth compared to the same period last year.
What guidance has Privia Health provided for FY 2025?
Privia Health raised its guidance for FY 2025 to above the high end range for several financial metrics, including Practice Collections and Adjusted EBITDA.
What were the Adjusted EBITDA figures for Q2 2025?
Adjusted EBITDA for Q2 2025 was $29.0 million, reflecting a 31.6% increase compared to Q2 2024.
How many Implemented Providers does Privia Health have?
As of June 30, 2025, Privia Health had 5,125 Implemented Providers, which is a 13.8% increase from the previous year.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRVA Insider Trading Activity
$PRVA insiders have traded $PRVA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $PRVA stock by insiders over the last 6 months:
- PARTH MEHROTRA (Chief Executive Officer) has made 0 purchases and 7 sales selling 91,595 shares for an estimated $2,198,404.
- DAVID MOUNTCASTLE (EVP & Chief Financial Officer) has made 0 purchases and 5 sales selling 18,248 shares for an estimated $431,046.
- MATTHEW SHAWN MORRIS sold 10,309 shares for an estimated $240,508
- EDWARD C FARGIS (EVP & General Counsel) has made 0 purchases and 2 sales selling 4,967 shares for an estimated $120,255.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PRVA Hedge Fund Activity
We have seen 123 institutional investors add shares of $PRVA stock to their portfolio, and 108 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,555,698 shares (-94.2%) from their portfolio in Q1 2025, for an estimated $79,825,420
- VAN BERKOM & ASSOCIATES INC. added 2,013,672 shares (+inf%) to their portfolio in Q1 2025, for an estimated $45,206,936
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,693,870 shares (+180.4%) to their portfolio in Q1 2025, for an estimated $38,027,381
- BANK OF AMERICA CORP /DE/ added 1,541,032 shares (+150.8%) to their portfolio in Q1 2025, for an estimated $34,596,168
- SOROS FUND MANAGEMENT LLC removed 700,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $15,715,000
- SILVERCREST ASSET MANAGEMENT GROUP LLC added 572,329 shares (+inf%) to their portfolio in Q1 2025, for an estimated $12,848,786
- RIVERBRIDGE PARTNERS LLC removed 569,799 shares (-10.3%) from their portfolio in Q2 2025, for an estimated $13,105,377
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PRVA Analyst Ratings
Wall Street analysts have issued reports on $PRVA in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 07/09/2025
- JP Morgan issued a "Overweight" rating on 05/28/2025
- JMP Securities issued a "Market Outperform" rating on 04/28/2025
- Baird issued a "Outperform" rating on 04/15/2025
- Truist Securities issued a "Buy" rating on 04/10/2025
- Needham issued a "Buy" rating on 04/10/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 02/28/2025
To track analyst ratings and price targets for $PRVA, check out Quiver Quantitative's $PRVA forecast page.
$PRVA Price Targets
Multiple analysts have issued price targets for $PRVA recently. We have seen 11 analysts offer price targets for $PRVA in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Elizabeth Anderson from Evercore ISI Group set a target price of $28.0 on 07/09/2025
- Lisa Gill from JP Morgan set a target price of $32.0 on 05/28/2025
- Andrew Mok from Barclays set a target price of $24.0 on 05/27/2025
- Constantine Davides from JMP Securities set a target price of $29.0 on 04/28/2025
- Michael Ha from Baird set a target price of $26.0 on 04/15/2025
- Jailendra Singh from Truist Securities set a target price of $28.0 on 04/10/2025
- Matthew Sheerin from Needham set a target price of $30.0 on 04/10/2025
Full Release
- Very Strong First Half Performance Across All Key Operating and Financial Metrics
- Implemented Providers +13.8% and Practice Collections +18.5% compared to 2Q’24
-
Guidance Raised to Above High End of Range for Practice Collections, GAAP Revenue, Platform Contribution and Adjusted EBITDA
c
ARLINGTON, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the second quarter ended June 30, 2025.
Second Quarter Performance
| For the Three Months Ended June 30, | |||||||||
| ($ in millions, except per share amounts) | 2025 | 2024 | Change (%) | ||||||
| Total revenue | $ | 521.2 | $ | 422.3 | 23.4 | % | |||
| Gross profit | $ | 112.8 | $ | 98.3 | 14.8 | % | |||
| Operating income | $ | 3.3 | $ | 5.1 | (34.6)% | ||||
| Net income a | $ | 2.7 | $ | 3.5 | (22.5)% | ||||
| Non-GAAP adjusted net income b d e | $ | 30.6 | $ | 23.5 | 30.1 | % | |||
| Net income per share | $ | 0.02 | $ | 0.03 | (33.3)% | ||||
| Non-GAAP adjusted net income per share b d e | $ | 0.24 | $ | 0.19 | 26.3 | % | |||
| a. | Net income for the three months ended June 30, 2025, included $18.8 million in non-cash stock compensation expense. Net income for the three months ended June 30, 2024 included $14.4 million in non-cash stock compensation expense. |
| b. | Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release. |
Second Quarter 2025 highlights include:
- Continued strength in same-store growth and new provider additions, +13.8% versus 2Q’24;
- Practice Collections of $862.9 million, +18.5% versus 2Q’24;
- Adjusted EBITDA b d e of $29.0 million, +31.6% versus 2Q’24;
- Strong sales and business development pipeline; and
-
Cash of $390.1 million and no debt following $95 million deployed for IMS transaction in Arizona.
Key Operating and Non-GAAP Financial Metrics b, d, e
| For the Three Months Ended June 30, | |||||||||
| ($ in millions) | 2025 | 2024 | Change (%) | ||||||
| Implemented Providers | 5,125 | 4,504 | 13.8 | % | |||||
| Value-Based Care Attributed Lives | 1,382,000 | 1,200,000 | 15.2 | % | |||||
| Practice Collections | $ | 862.9 | $ | 728.0 | 18.5 | % | |||
| Care Margin b d | $ | 115.2 | $ | 99.8 | 15.4 | % | |||
| Platform Contribution b d | $ | 57.5 | $ | 47.4 | 21.3 | % | |||
| Adjusted EBITDA b d e | $ | 29.0 | $ | 22.0 | 31.6 | % | |||
Six-Month Performance
| For the Six Months Ended June 30, | |||||||||
| ($ in millions, except per share amounts) | 2025 | 2024 | Change (%) | ||||||
| Total revenue | $ | 1,001.3 | $ | 837.6 | 19.5 | % | |||
| Gross profit | $ | 216.4 | $ | 191.6 | 12.9 | % | |||
| Operating income | $ | 8.6 | $ | 5.9 | 44.5 | % | |||
| Net income a | $ | 6.9 | $ | 6.5 | 7.1 | % | |||
| Non-GAAP adjusted net income b d e | $ | 58.4 | $ | 46.1 | 26.8 | % | |||
| Net income per share | $ | 0.05 | $ | 0.05 | — | % | |||
| Non-GAAP adjusted net income per share b d e | $ | 0.46 | $ | 0.37 | 24.3 | % | |||
| a. | Net income for the six months ended June 30, 2025 included $36.6 million in non-cash stock compensation expense. Net income for the six months ended June 30, 2024 included $26.3 million in non-cash stock compensation expense. |
| b. | Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release. |
Key Operating and Non-GAAP Financial Metrics
b d e
| For the Six Months Ended June 30, | |||||||||
| ($ in millions) | 2025 | 2024 | Change (%) | ||||||
| Practice Collections | $ | 1,661.5 | $ | 1,435.7 | 15.7 | % | |||
| Care Margin b d | $ | 220.4 | $ | 194.7 | 13.2 | % | |||
| Platform Contribution b d | $ | 109.2 | $ | 92.1 | 18.5 | % | |||
| Adjusted EBITDA b d e | $ | 55.9 | $ | 41.9 | 33.3 | % | |||
Updated FY’25 Guidance c d e f
Privia Health raised its full-year 2025 outlook as follows:
| FY 2024 | Initial FY 2025 Guidance at 2.27.25 c |
Updated FY 2025 Guidance at 8.7.25
|
||||||||
| ($ in millions) | Actual | Low | High | |||||||
| Implemented Providers | 4,789 | 5,200 | 5,300 | High End | ||||||
| Attributed Lives | 1,256,000 | 1,300,000 | 1,400,000 | High End | ||||||
| Practice Collections | $ | 2,968.0 | $ | 3,150 | $ | 3,250 | Above High End | |||
| GAAP Revenue | $ | 1,736.4 | $ | 1,800 | $ | 1,900 | Above High End | |||
| Care Margin c d | $ | 403.9 | $ | 435 | $ | 445 | High End | |||
| Platform Contribution c d | $ | 195.6 | $ | 208 | $ | 218 | Above High End | |||
| Adjusted EBITDA c d e | $ | 90.5 | $ | 105 | $ | 110 | Above High End | |||
- Guidance includes impact of Arizona market entry, and assumes no other new business development activity
- De minimis capital expenditures expected in full-year 2025
- At least 80% of Adjusted EBITDA expected to convert to free cash flow in full-year 2025
| c. |
Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of gross margin, operating income and net income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.
|
| d. |
See “Key Metrics and Non-GAAP Financial Measures” for more information as to how the Company defines and calculates Implemented Providers, Attributed Lives, Practice Collections, Care Margin, Platform Contribution, and Adjusted EBITDA, and for a reconciliation of the most comparable GAAP measures to Care Margin, Platform Contribution, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Per Share.
|
| e. |
Certain non-recurring or non-cash and other expenses will be treated as an add back in the reconciliation of Net Income to Adjusted EBITDA, and the reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share, the details of which can be found in the Reconciliation schedules near the end of this and in future quarterly press releases.
|
| f. | Any slight variations in totals due to rounding. |
Webcast and Conference Call Information
The Company will host a conference call on August 7, 2025, at 8:00 am ET to discuss these results and management’s outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-events/events-and-presentations to listen to the call via webcast. The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link. If you wish to participate in the live conference call, then please dial 888-596-4144 (or 646-968-2525 for international callers) and provide Conference ID 5704885.
This news release and the financial statements contained herein, and the slide presentation for the webcast, are also available on the Privia Health Investor Relations website at ir.priviahealth.com .
About Privia Health
Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 15 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 5.3+ million patients, and reward 5,100+ physicians and advanced practitioners for delivering high-value care.
Privia’s mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com and connect with us on LinkedIn.
Non-GAAP Financial Measures
The Company reports and discusses its operating results using financial measures consistent with accounting principles generally accepted in the United States ("GAAP"). From time to time, in press releases, financial presentations, earnings conference calls or otherwise, the Company may disclose certain non-GAAP financial measures. The non-GAAP financial measures presented in this press release should not be viewed as alternatives or substitutes for the Company's reported GAAP results. A reconciliation to the most directly comparable GAAP financial measure is set forth in the tables that accompany this release.
The Company believes that the non-GAAP financial measures presented in this press release are relevant and provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because the measures allow them to understand and compare the Company's actual and expected operating results during the prior, current and future periods in a more consistent manner. The non-GAAP measures presented in this press release may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provides a more complete understanding of the results of operations and trends affecting the Company's business. These non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to financial measures calculated in accordance with GAAP.
Safe Harbor Statement
The financial results in this press release reflect preliminary, unaudited results, which are not final until the Company’s Form 10-Q is filed with the Securities and Exchange Commission (“SEC”). This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” "assumes," “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things: our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full-year guidance for 2025. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements.
Factors related to these risks and uncertainties include, but are not limited to: the heavily regulated industry in which we operate, and any failure by us or our medical groups to comply with the extensive applicable healthcare laws and government regulations; the complexity of the legal framework governing our relationships with Medical Groups, some of which we do not own, and Privia providers, and the impact of legal challenges or shifting interpretations of applicable laws; the execution of our growth strategy, which may not prove viable and we may not realize expected results; difficulties timely implementing our proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups; the high level of competition in our industry; challenges in successfully establishing a presence in new geographic markets; the impact of failures by or service disruptions at key third-party vendors, such as our primary electronic medical record vendor, athenahealth, Inc.; potential decreases in reimbursement rates by governmental and third-party payers, changes to payment terms or challenges negotiating and retaining favorable contracts with private third-party payers, and changes impacting our patient population; the financial and operational impact of our compliance with various complex and changing federal and state privacy and security laws and regulations related to our use, disclosure, and other processing of personal information and protected health information, including the Health Insurance Portability and Accountability Act of 1996; the impact of actual and potential security threats, cybersecurity incidents or privacy or other forms of data breaches involving us, our vendors or other third parties; the continued availability of qualified workforce, including staff at our medical groups, and the continued upward pressure on compensation for such workforce; and other risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent Quarterly Reports on Form 10-Q. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
| Contact: |
| Robert Borchert |
| SVP, Investor & Corporate Communications |
| [email protected] |
| 817.783.4841 |
|
Privia Health Group, Inc.
Condensed Consolidated Statements of Operations (g) (unaudited) (in thousands, except share and per share data) |
|||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||
| Revenue | $ | 521,153 | $ | 422,326 | $ | 1,001,250 | $ | 837,569 | |||
| Operating expenses: | |||||||||||
| Provider expense | 405,992 | 322,536 | 780,801 | 642,872 | |||||||
| Cost of platform | 64,918 | 57,106 | 124,444 | 111,163 | |||||||
| Sales and marketing | 6,805 | 6,852 | 13,727 | 12,937 | |||||||
| General and administrative | 37,519 | 28,916 | 69,240 | 61,037 | |||||||
| Depreciation and amortization | 2,583 | 1,818 | 4,484 | 3,639 | |||||||
| Total operating expenses | 517,817 | 417,228 | 992,696 | 831,648 | |||||||
| Operating income | 3,336 | 5,098 | 8,554 | 5,921 | |||||||
| Interest income, net | 2,408 | 2,966 | 5,339 | 5,950 | |||||||
| Income before provision for income taxes | 5,744 | 8,064 | 13,893 | 11,871 | |||||||
| Provision for income taxes | 2,456 | 3,421 | 4,559 | 4,172 | |||||||
| Net income | 3,288 | 4,643 | 9,334 | 7,699 | |||||||
| Less: Net income attributable to non-controlling interests | 601 | 1,176 | 2,427 | 1,248 | |||||||
| Net income attributable to Privia Health Group, Inc. | $ | 2,687 | $ | 3,467 | $ | 6,907 | $ | 6,451 | |||
| Net income per share attributable to Privia Health Group, Inc. stockholders – basic | $ | 0.02 | $ | 0.03 | $ | 0.06 | $ | 0.05 | |||
| Net income per share attributable to Privia Health Group, Inc. stockholders – diluted | $ | 0.02 | $ | 0.03 | $ | 0.05 | $ | 0.05 | |||
| Weighted average common shares outstanding – basic | 122,132,245 | 119,301,350 | 121,370,949 | 118,902,095 | |||||||
| Weighted average common shares outstanding – diluted | 128,447,069 | 125,317,908 | 128,149,252 | 125,315,681 | |||||||
(g) Any slight variations in totals due to rounding.
|
Privia Health Group, Inc.
Condensed Consolidated Balance Sheets (h) (in thousands) |
|||||||
| June 30, 2025 | December 31, 2024 | ||||||
| Assets | (unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 390,127 | $ | 491,149 | |||
| Accounts receivable | 443,994 | 316,179 | |||||
| Prepaid expenses and other current assets | 48,839 | 27,495 | |||||
| Total current assets | 882,960 | 834,823 | |||||
| Non-current assets: | |||||||
| Property and equipment, net | 827 | 1,242 | |||||
| Operating right-of-use asset | 6,038 | 4,828 | |||||
| Intangible assets, net | 170,140 | 109,807 | |||||
| Goodwill | 172,215 | 141,615 | |||||
| Deferred tax asset | 23,712 | 26,383 | |||||
| Other non-current assets | 16,650 | 17,085 | |||||
| Total non-current assets | 389,582 | 300,960 | |||||
| Total assets | $ | 1,272,542 | $ | 1,135,783 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued expenses | $ | 74,299 | $ | 81,986 | |||
| Provider liability | 458,053 | 364,607 | |||||
| Operating lease liabilities, current | 2,502 | 2,553 | |||||
| Total current liabilities | 534,854 | 449,146 | |||||
| Non-current liabilities: | |||||||
| Operating lease liabilities, non-current | 4,142 | 3,037 | |||||
| Other non-current liabilities | — | 153 | |||||
| Total non-current liabilities | 4,142 | 3,190 | |||||
| Total liabilities | 538,996 | 452,336 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Common stock | 1,227 | 1,203 | |||||
| Additional paid-in capital | 853,950 | 813,209 | |||||
| Accumulated deficit | (172,322 | ) | (179,229 | ) | |||
| Total Privia Health Group, Inc. stockholders’ equity | 682,855 | 635,183 | |||||
| Non-controlling interest | 50,691 | 48,264 | |||||
| Total stockholders’ equity | 733,546 | 683,447 | |||||
| Total liabilities and stockholders’ equity | $ | 1,272,542 | $ | 1,135,783 | |||
(h) Any slight variations in totals are due to rounding.
|
Privia Health Group, Inc.
Condensed Consolidated Statements of Cash Flows ( i ) (unaudited) (in thousands) |
|||||||
| For the Six Months Ended June 30, | |||||||
| 2025 | 2024 | ||||||
| Cash flows from operating activities | |||||||
| Net income | $ | 9,334 | $ | 7,699 | |||
| Adjustments to reconcile net income to net cash (used in) provided by operating activities: | |||||||
| Depreciation | 415 | 585 | |||||
| Amortization of intangibles | 4,069 | 3,054 | |||||
| Stock-based compensation | 36,639 | 26,295 | |||||
| Deferred tax expense | 2,671 | 3,896 | |||||
| Changes in asset and liabilities: | |||||||
| Accounts receivable | (121,497 | ) | (79,287 | ) | |||
| Prepaid expenses and other current assets | (21,344 | ) | (1,739 | ) | |||
| Other non-current assets and right-of-use asset | 1,055 | (676 | ) | ||||
| Accounts payable and accrued expenses | (7,687 | ) | 2,987 | ||||
| Provider liability | 81,185 | 40,047 | |||||
| Operating lease liabilities | (778 | ) | (1,531 | ) | |||
| Other long-term liabilities | (153 | ) | — | ||||
| Net cash (used in) provided by operating activities | (16,097 | ) | 1,330 | ||||
| Cash from investing activities | |||||||
| Business acquisitions, net of cash acquired | (89,058 | ) | (707 | ) | |||
| Other | — | (5,006 | ) | ||||
| Net cash used in investing activities | (89,058 | ) | (5,713 | ) | |||
| Cash flows from financing activities | |||||||
| Proceeds from exercised stock options | 4,126 | 1,224 | |||||
| Proceeds from non-controlling interest | — | 1,000 | |||||
| Net cash provided by financing activities | 4,126 | 2,224 | |||||
| Net decrease in cash and cash equivalents | (101,022 | ) | (2,159 | ) | |||
| Cash and cash equivalents at beginning of period | 491,149 | 389,511 | |||||
| Cash and cash equivalents at end of period | $ | 390,127 | $ | 387,352 | |||
| Supplemental disclosure of cash flow information: | |||||||
| Interest paid | $ | 124 | $ | 156 | |||
| Income taxes paid | $ | 5,771 | $ | 2,881 | |||
| Supplemental disclosure of non-cash operating activities: | |||||||
| Lease liabilities obtained in exchange for right-of-use assets | $ | 1,832 | $ | — | |||
( i ) Any slight variations in totals are due to rounding.
Additional Financial Information
Revenues disaggregated by source:
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||
| (Dollars in Thousands) | 2025 | 2024 | 2025 | 2024 | |||||||
| FFS-patient care | $ | 331,464 | $ | 275,761 | $ | 643,225 | $ | 550,584 | |||
| FFS-administrative services | 35,116 | 32,132 | 67,371 | 61,208 | |||||||
| Capitated revenue | 75,511 | 56,438 | 146,201 | 107,742 | |||||||
| Shared savings | 60,021 | 39,818 | 107,933 | 87,282 | |||||||
| Care management fees (PMPM) | 16,919 | 16,163 | 32,121 | 26,766 | |||||||
| Other revenue | 2,122 | 2,014 | 4,399 | 3,987 | |||||||
| Total Revenue | $ | 521,153 | $ | 422,326 | $ | 1,001,250 | $ | 837,569 | |||
The Company’s liabilities for unpaid medical claims under at-risk capitation arrangements:
| June 30, | ||||||||
| (Dollars in Thousands) | 2025 | 2024 | ||||||
| Balance, beginning of period | $ | 66,355 | $ | 67,138 | ||||
| Incurred health care costs: | ||||||||
| Current year | 144,840 | 104,610 | ||||||
| Prior years | (555 | ) | 3,305 | |||||
| Total claims incurred | $ | 144,285 | $ | 107,915 | ||||
| Claims paid: | ||||||||
| Current year | (63,025 | ) | (47,979 | ) | ||||
| Prior year | (47,959 | ) | (52,877 | ) | ||||
| Total claims paid | $ | (110,984 | ) | $ | (100,856 | ) | ||
| Balance, end of period | $ | 99,656 | $ | 74,197 | ||||
Key Metrics and Non-GAAP Financial Measures
Privia Health reviews a number of operating and financial metrics, including the following key metrics and non-GAAP financial measures, to evaluate the Company’s business, measure performance, identify trends affecting the Company’s business, formulate business plans, and make strategic decisions.
Key Metrics (j)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||
| (unaudited; $ in millions) | 2025 | 2024 | 2025 | 2024 | ||||||||
| Implemented Providers (as of end of period) (1) | 5,125 | 4,504 | 5,125 | 4,504 | ||||||||
| Attributed Lives (as of end of period) (2) | 1,382,000 | 1,200,000 | 1,382,000 | 1,200,000 | ||||||||
| Practice Collections (3) | $ | 862.9 | $ | 728.0 | $ | 1,661.5 | $ | 1,435.7 | ||||
| (1) Implemented Providers is defined as the total of all service professionals on Privia Health’s platform at the end of a given period who are credentialed by Privia Health and billed for medical services, in both Owned and Non-Owned Medical Groups during that period. | ||||||||||||
| (2) Attributed Lives are defined as any patient that a payer deems attributed to Privia to deliver care as part of a value-based care arrangement through a provider of primary care services as of the end of a particular period. | ||||||||||||
| (3) Practice Collections are defined as the total collections from all practices in all markets and all sources of reimbursement that the Company receives for delivering care and providing Privia Health’s platform and associated services. Practice Collections differ from revenue by including collections from Non-Owned Medical Groups. | ||||||||||||
| (j) Any slight variations in totals are due to rounding. | ||||||||||||
Non-GAAP Financial Measures
(4)(k)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| (unaudited; $ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Care Margin | $ | 115,161 | $ | 99,790 | $ | 220,449 | $ | 194,697 | ||||||||
| Platform Contribution | $ | 57,466 | $ | 47,394 | $ | 109,199 | $ | 92,131 | ||||||||
| Platform Contribution Margin | 49.9% | 47.5% | 49.5% | 47.3% | ||||||||||||
| Adjusted EBITDA | $ | 28,992 | $ | 22,023 | $ | 55,907 | $ | 41,945 | ||||||||
| Adjusted EBITDA Margin | 25.2% | 22.1% | 25.4% | 21.5% | ||||||||||||
(4)
In addition to results reported in accordance with GAAP, Privia Health discloses Care Margin, Platform Contribution, Platform Contribution margin, Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. Each are defined as follows:
|
||||||||||||||||
| (k) Any slight variations in totals are due to rounding. | ||||||||||||||||
Reconciliation of Gross Profit to Care Margin
(l)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| (unaudited; $ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue | $ | 521,153 | $ | 422,326 | $ | 1,001,250 | $ | 837,569 | ||||||||
| Provider expense | (405,992 | ) | (322,536 | ) | (780,801 | ) | (642,872 | ) | ||||||||
| Amortization of intangible assets | (2,396 | ) | (1,527 | ) | (4,069 | ) | (3,054 | ) | ||||||||
| Gross Profit | $ | 112,765 | $ | 98,263 | $ | 216,380 | $ | 191,643 | ||||||||
| Amortization of intangibles assets | 2,396 | 1,527 | 4,069 | 3,054 | ||||||||||||
| Care margin | $ | 115,161 | $ | 99,790 | $ | 220,449 | $ | 194,697 | ||||||||
| (l) Any slight variations in totals are due to rounding. | ||||||||||||||||
Reconciliation of Gross Profit to Platform Contribution
(m)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| (unaudited; $ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue | $ | 521,153 | $ | 422,326 | $ | 1,001,250 | $ | 837,569 | ||||||||
| Provider expense | (405,992 | ) | (322,536 | ) | (780,801 | ) | (642,872 | ) | ||||||||
| Amortization of intangibles assets | (2,396 | ) | (1,527 | ) | (4,069 | ) | (3,054 | ) | ||||||||
| Gross Profit | $ | 112,765 | $ | 98,263 | $ | 216,380 | $ | 191,643 | ||||||||
| Amortization of intangibles assets | 2,396 | 1,527 | 4,069 | 3,054 | ||||||||||||
| Cost of platform | (64,918 | ) | (57,106 | ) | (124,444 | ) | (111,163 | ) | ||||||||
| Stock-based compensation (5) | 7,223 | 4,710 | 13,194 | 8,597 | ||||||||||||
| Platform Contribution | $ | 57,466 | $ | 47,394 | $ | 109,199 | $ | 92,131 | ||||||||
| (m) Any slight variations in totals are due to rounding. | ||||||||||||||||
| (5) Amount represents stock-based compensation expense included in Cost of Platform. | ||||||||||||||||
Reconciliation of Net Income to Adjusted EBITDA
(n)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| (unaudited; $ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net income | $ | 2,687 | $ | 3,467 | $ | 6,907 | $ | 6,451 | ||||||||
| Net income attributable to non-controlling interests | 601 | 1,176 | 2,427 | 1,248 | ||||||||||||
| Provision for income taxes | 2,456 | 3,421 | 4,559 | 4,172 | ||||||||||||
| Interest income, net | (2,408 | ) | (2,966 | ) | (5,339 | ) | (5,950 | ) | ||||||||
| Depreciation and amortization | 2,583 | 1,818 | 4,484 | 3,639 | ||||||||||||
| Stock-based compensation | 18,849 | 14,391 | 36,639 | 26,295 | ||||||||||||
| Other expenses (6) | 4,224 | 716 | 6,230 | 6,090 | ||||||||||||
| Adjusted EBITDA | $ | 28,992 | $ | 22,023 | $ | 55,907 | $ | 41,945 | ||||||||
| (n) Any slight variations in totals are due to rounding. | ||||||||||||||||
| (6) Other expenses include employer taxes on equity vesting/exercises, severance and certain non-recurring costs. | ||||||||||||||||
Reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share
(o)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||
| (unaudited; $ in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||
| Net income | $ | 2,687 | $ | 3,467 | $ | 6,907 | $ | 6,451 | |||
| Stock-based compensation | 18,849 | 14,391 | 36,639 | 26,295 | |||||||
| Intangible amortization expense | 2,396 | 1,527 | 4,069 | 3,054 | |||||||
| Provision for income tax | 2,456 | 3,421 | 4,559 | 4,172 | |||||||
| Other expenses (7) | 4,224 | 716 | 6,230 | 6,090 | |||||||
| Adjusted net income | $ | 30,612 | $ | 23,522 | $ | 58,404 | $ | 46,062 | |||
| Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic | $ | 0.25 | $ | 0.20 | $ | 0.48 | $ | 0.39 | |||
| Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted | $ | 0.24 | $ | 0.19 | $ | 0.46 | $ | 0.37 | |||
| Weighted average common shares outstanding – basic | 122,132,245 | 119,301,350 | 121,370,949 | 118,902,095 | |||||||
| Weighted average common shares outstanding – diluted | 128,447,069 | 125,317,908 | 128,148,252 | 125,315,681 | |||||||
| (o) Any slight variations in totals due to rounding. | |||||||||||
| (7) Other expenses include employer taxes on equity vesting/exercises, severance and certain non-recurring costs. | |||||||||||